<DOC>
	<DOC>NCT02545101</DOC>
	<brief_summary>This is a retrospective chart review non-interventional study designed to collect real world data on the use and outcomes of tolvaptan for the treatment of patients with hyponatraemia secondary to syndrome of inappropriate antidiuretic hormone (SIADH) secretion.</brief_summary>
	<brief_title>An Observational Study on Real-world Use and Outcomes of Patients Treated With Tolvaptan for Hyponatraemia Due to SIADH</brief_title>
	<detailed_description />
	<mesh_term>Hyponatremia</mesh_term>
	<mesh_term>Inappropriate ADH Syndrome</mesh_term>
	<mesh_term>Tolvaptan</mesh_term>
	<criteria>Provision of patient informed consent unless a) not required by local regulations, b) it would take a non reasonable effort or c) if the source patient is deceased or untraceable. Female and/or male patients aged 18 years and over. Patients who received at least 2 doses of tolvaptan, for the treatment of one occurrence of hyponatraemia secondary to SIADH. A patient cannot take part in this study if participating in any other clinical study in which the medicinal product aims to treat the causes or symptoms of hyponatraemia at the time of the hyponatraemia episode being documented in the current study.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Hyponatremia due to SIADH</keyword>
	<keyword>tolvaptan</keyword>
</DOC>